To evaluate the efficacy of ethosuximide in reducing abdominal pain in patients with irritable bowel syndrome (IBS) compared to placebo.
Approach:
Key Findings:
27% of ethosuximide patients met responder criteria vs 23% in the placebo group, a difference that was not statistically significant.
Higher discontinuation rate in the ethosuximide group (47%) compared to placebo (22%), which may affect the overall interpretation of efficacy.
Common adverse events included headache, sleep disturbance, fatigue, nausea, abdominal pain, and dizziness, with a higher incidence in the ethosuximide group.
Interpretation:
Ethosuximide did not demonstrate a significant improvement in abdominal pain compared to placebo and was associated with a higher rate of adverse events leading to treatment discontinuation, raising concerns about its safety profile.
Limitations:
Higher discontinuation rates in the ethosuximide group may affect the interpretation of response rates, as those who dropped out may have had worse outcomes.
Secondary endpoints showed no significant differences between groups, indicating a lack of overall benefit.
Conclusion:
Ethosuximide was not effective in improving abdominal pain in IBS patients and had a less favorable safety profile. Future studies may explore more selective T-type calcium channel modulators.
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
